SAN DIEGO, CA -- (Marketwired) -- 10/31/13 --
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the following upcoming conferences:
- Canaccord Genuity Medical Technology & Diagnostics Forum at the Westin New York Grand Central hotel in New York, New York on Thursday, November 14, 2013 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time).
- Piper Jaffray 25th Annual Healthcare Conference at the New York Palace hotel in New York, New York on Tuesday, December 3, 2013 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time).
Douglas Bryant, president and chief executive officer, will present on the specified days with a question and answer session scheduled immediately following the presentations. During the presentations, the company will discuss business and financial developments and trends. The company's statements may contain or constitute material information that has not been previously disclosed.
A live webcast and audio archive of the presentations will be available via the Investor Relations section of the company's Web site at www.quidel.com. Participants should allow approximately five to ten minutes prior to each presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of each webcast will also be available on the company's Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue®, D3® Direct Detection and Thyretain® leading brand names, as well as under the new Sofia® and AmpliVue® brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.
Chief Financial Officer
Media and Investors Contact: